Therapeutic Antibody Comparison Matrix

Therapeutic Antibody Comparison Matrix

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Therapeutic Antibody Comparison Matrix</th>
</tr>
<tr>
<td class="label">Developer</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Soluble Aβ protofibrils</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Selectively binds soluble Aβ protofibrils with ~10-fold higher affinity than monomers, 1000-fold higher than plaques</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Full approval (2023)</td>
</tr>
<tr>
<td class="label">Phase 3 Trial</td>
<td>CLARITY-AD</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>27% slowing of decline on CDR-SB at 18 months</td>
</tr>
<tr>
<td class="label">CDR-SB Change</td>
<td>1.21 vs 1.66 (placebo), difference = 0.45 (p<0.001)</td>
</tr>
<tr>
<td class="label">Amyloid PET Reduction</td>
<td>55.5 centiloids at 18 months</td>
</tr>
<tr>
<td class="label">Plasma [p-tau217](/biomarkers/p-tau-217)</td>
<td>23% decrease from baseline</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Bi-weekly IV infusion (10 mg/kg)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>12.6% (vs 1.7% placebo)</td>
</tr>
<tr>
<td class="label">ARIA-H Rate</td>
<td>17.3% (vs 8.7% placebo)</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td

Therapeutic Antibody Comparison Matrix

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Therapeutic Antibody Comparison Matrix</th>
</tr>
<tr>
<td class="label">Developer</td>
<td>Eisai/Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Soluble Aβ protofibrils</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Selectively binds soluble Aβ protofibrils with ~10-fold higher affinity than monomers, 1000-fold higher than plaques</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Full approval (2023)</td>
</tr>
<tr>
<td class="label">Phase 3 Trial</td>
<td>CLARITY-AD</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>27% slowing of decline on CDR-SB at 18 months</td>
</tr>
<tr>
<td class="label">CDR-SB Change</td>
<td>1.21 vs 1.66 (placebo), difference = 0.45 (p<0.001)</td>
</tr>
<tr>
<td class="label">Amyloid PET Reduction</td>
<td>55.5 centiloids at 18 months</td>
</tr>
<tr>
<td class="label">Plasma [p-tau217](/biomarkers/p-tau-217)</td>
<td>23% decrease from baseline</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Bi-weekly IV infusion (10 mg/kg)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>12.6% (vs 1.7% placebo)</td>
</tr>
<tr>
<td class="label">ARIA-H Rate</td>
<td>17.3% (vs 8.7% placebo)</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Pyroglutamate-modified Aβ (pE3-Aβ)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Targets highly aggregation-prone species found in plaques; enhanced Fc-mediated effector function</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Full approval (2024)</td>
</tr>
<tr>
<td class="label">Phase 3 Trial</td>
<td>TRAILBLAZER-ALZ 2</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>35% slowing on iADRS, 36% on CDR-SB in low-to-medium tau patients</td>
</tr>
<tr>
<td class="label">Plaque Clearance</td>
<td>84% of patients achieved clearance at 76 weeks</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion; treatment can be stopped upon plaque clearance</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>24% (vs 2.1% placebo)</td>
</tr>
<tr>
<td class="label">Key Feature</td>
<td>Allows treatment discontinuation after plaque clearance</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Conformational epitopes on Aβ aggregates (plaques and oligomers)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Human IgG1 antibody; promotes plaque clearance via [microglia](/cell-types/microglia-neuroinflammation)</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Accelerated approval (2021), withdrawn from market (2024)</td>
</tr>
<tr>
<td class="label">Phase 3 Trials</td>
<td>EMERGE (positive), ENGAGE (negative)</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>High-dose EMERGE: 22% slowing on CDR-SB</td>
</tr>
<tr>
<td class="label">Amyloid PET</td>
<td>Significant plaque reduction in both trials</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion (10 mg/kg)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>35.5% (high dose)</td>
</tr>
<tr>
<td class="label">Post-market Data</td>
<td>Real-world ARIA rates ~5%; mixed functional outcomes</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Conformational epitopes on Aβ fibrils and plaques</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Fully human IgG1; binds to aggregated Aβ</td>
</tr>
<tr>
<td class="label">FDA Status</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Phase 3 Trials</td>
<td>GRADUATE I & II</td>
</tr>
<tr>
<td class="label">Clinical Endpoint</td>
<td>Did not meet primary endpoint</td>
</tr>
<tr>
<td class="label">Subgroup Analysis</td>
<td>Potential benefit in lower tau pathology patients</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Subcutaneous injection (weekly)</td>
</tr>
<tr>
<td class="label">ARIA-E Rate</td>
<td>25%</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Genentech/Roche</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Mid-domain tau (aa 6-23)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Binds extracellular tau to block neuronal uptake and spreading</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2 (TAK-920/921)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Alzheimer's disease, PSP</td>
</tr>
<tr>
<td class="label">Trial Results</td>
<td>Phase 2 in AD: reduced CSF tau, no cognitive benefit; Phase 2 in PSP: reduced tau PET, slower progression</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">Target</td>
<td>N-terminal tau</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Targets extracellular tau to prevent propagation</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>AD, PSP</td>
</tr>
<tr>
<td class="label">Trial Results</td>
<td>Did not meet primary endpoint in PSP</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Target</td>
<td>N-terminal tau (fragment)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Binds extracellular tau to block seeding</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 2 (discontinued)</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>AD, PSP</td>
</tr>
<tr>
<td class="label">Trial Results</td>
<td>Discontinued after Phase 2 did not meet primary endpoint</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Monthly IV infusion</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Johnson & Johnson</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Phospho-tau (specific epitopes)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Targets phosphorylated tau species</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Lundbeck</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Phospho-tau (p-tau)</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Anti-phospho-tau antibody</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Alzheimer's disease</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>[Lecanemab](/entities/lecanemab)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">FDA Approved</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Primary Indication</td>
<td>Early AD</td>
</tr>
<tr>
<td class="label">Trial Population</td>
<td>MCI-mild AD</td>
</tr>
<tr>
<td class="label">Clinical Effect Size</td>
<td>27% slower</td>
</tr>
<tr>
<td class="label">Plaque Clearance</td>
<td>55-70%</td>
</tr>
<tr>
<td class="label">Tau PET Reduction</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Biomarker Response</td>
<td>p-tau217 ↓</td>
</tr>
<tr>
<td class="label">Treatment Duration</td>
<td>Ongoing</td>
</tr>
<tr>
<td class="label">Dosing Frequency</td>
<td>Bi-weekly</td>
</tr>
<tr>
<td class="label">Route</td>
<td>IV infusion</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>ARIA-E (edema)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>24.0%</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>35.5% (high dose)</td>
</tr>
<tr>
<td class="label">Anti-tau</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Anti-Amyloid</td>
</tr>
<tr>
<td class="label">Disease Stage</td>
<td>MCI to mild dementia</td>
</tr>
<tr>
<td class="label">Amyloid Status</td>
<td>Must be amyloid-positive</td>
</tr>
<tr>
<td class="label">Tau Status</td>
<td>Lower tau = better response</td>
</tr>
<tr>
<td class="label">Age</td>
<td><80 years optimal</td>
</tr>
<tr>
<td class="label">APOE4 Status</td>
<td>Monitor closely if carrier</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Anti-Amyloid Use</td>
</tr>
<tr>
<td class="label">Amyloid PET</td>
<td>Confirm baseline, monitor clearance</td>
</tr>
<tr>
<td class="label">Tau PET</td>
<td>Secondary endpoint</td>
</tr>
<tr>
<td class="label">Plasma p-tau217</td>
<td>Treatment response</td>
</tr>
<tr>
<td class="label">Plasma p-tau181</td>
<td>Emerging</td>
</tr>
<tr>
<td class="label">CSF total tau</td>
<td>Secondary</td>
</tr>
<tr>
<td class="label">CSF p-tau</td>
<td>Secondary</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Anti-Amyloid</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>9</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>8</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>9</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>8</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>6</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>5</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>9</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
</table>

This page provides a comprehensive comparison of monoclonal antibodies targeting [amyloid-beta](/proteins/amyloid-beta) (anti-amyloid) and [tau protein](/proteins/tau) (anti-tau) in Alzheimer's disease and related neurodegenerative disorders. These disease-modifying therapies represent the cutting edge of Alzheimer's treatment with three anti-amyloid antibodies now FDA-approved and multiple anti-tau antibodies in clinical development.

Anti-Amyloid Antibodies

Lecanemab (Leqembi)

Donanemab (Kisunla)

Aducanumab (Aduhelm)

Gantenerumab (Roche)

Anti-Tau Antibodies in Development

Semorinemab (RO7105705)

Tilavonemab (ABBV-8E12)

Gosuranemab (BIIB092)

JNJ-63742057

Lu AF87908

Direct Comparison Matrix

Mechanism of Action Comparison

Anti-Amyloid Mechanism

Anti-Tau Mechanism

Safety Profile Comparison

ARIA Incidence by Antibody

Risk Mitigation Strategies

Clinical Implementation

Patient Selection Criteria

Biomarker Monitoring

Future Directions

Combination Therapy Approaches

Next-Generation Antibodies

• [Blood-brain barrier](/entities/blood-brain-barrier) penetration: Engineered antibodies with enhanced BBB transport
• Reduced ARIA risk: Modified Fc regions
• Dual-targeting: Bispecific antibodies
• Subcutaneous delivery: Improved convenience

Evidence Quality Assessment

Conclusion

Anti-amyloid antibodies (lecanemab, donanemab) have demonstrated disease-modifying effects in early Alzheimer's disease, representing a breakthrough in AD treatment. Anti-tau antibodies remain in development with mixed results—some showing biomarker effects but limited clinical benefit in AD, while showing more promise in pure tauopathies like PSP.

Key insights:

• Early intervention is critical for both approaches
• Patient selection (amyloid status, tau burden) significantly impacts outcomes
• ARIA remains a key safety consideration for anti-amyloid therapy
• Combination approaches may provide greater benefit than monotherapy
• Anti-tau therapy may complement anti-amyloid treatment for comprehensive disease modification

See Also

• [Anti-Amyloid Therapeutics](/therapeutics/anti-amyloid-therapeutics)
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Related Imaging Abnormalities (ARIA)](/diseases/amyloid-related-imaging-abnormalities-aria)
• [Biomarker-Guided Therapy](/therapeutics/biomarker-guided-therapy)
• [Clinical Trials Index](/therapeutics/clinical-trials-index)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT
• [Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BACE1
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
• [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1
• [Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery](/hypothesis/h-346639e8) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: TRAK1_KIF5A

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;